Urits Ivan, Clark Gavin, An Daniel, Wesp Bredan, Zhou Rebecca, Amgalan Ariunzaya, Berger Amnon A, Kassem Hisham, Ngo Anh L, Kaye Alan D, Kaye Rachel J, Cornett Elyse M, Viswanath Omar
Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
Georgetown University School of Medicine, Washington, DC, USA.
Pain Ther. 2020 Jun;9(1):195-215. doi: 10.1007/s40122-020-00159-3. Epub 2020 Mar 28.
Migraine headache is a common, chronic, debilitating disease with a complex etiology. Current therapy for migraine headache comprises either treatments targeting acute migraine pain or prophylactic therapy aimed at increasing the length of time between migraine episodes. Recent evidence suggests that calcium gene-related peptide (CGRP) is a critical component in the pathogenesis of migraines. Fremanezumab, a monoclonal antibody against CGRP, was recently approved by the Food and Drug Administration (FDA) after multiple studies showed that it was well-tolerated, safe, and effective in the treatment of migraines. Further research is needed to elucidate the long-term effects of fremanezumab and CGRP-antagonists in general, and additional data is required in less healthy patients to estimate its effects in these populations and potentially increase the eligible group of recipients. This is a comprehensive review of the current literature on the efficacy and safety of fremanezumab for the treatment of chronic migraine. In this review we provide an update on the epidemiology, pathogenesis, diagnosis, and current treatment of migraine, and summarize the evidence for fremanezumab as a treatment for migraine.
偏头痛是一种常见的慢性致残性疾病，病因复杂。目前偏头痛的治疗方法包括针对急性偏头痛疼痛的治疗或旨在延长偏头痛发作间隔时间的预防性治疗。最近的证据表明，钙基因相关肽（CGRP）是偏头痛发病机制中的关键成分。在多项研究表明抗CGRP单克隆抗体fremanezumab耐受性良好、安全且对偏头痛治疗有效后，它最近获得了美国食品药品监督管理局（FDA）的批准。总体而言，需要进一步研究以阐明fremanezumab和CGRP拮抗剂的长期影响，并且需要更多健康状况较差患者的数据来评估其在这些人群中的效果，并可能扩大适用人群范围。这是一篇关于fremanezumab治疗慢性偏头痛疗效和安全性的当前文献综述。在本综述中，我们提供了偏头痛流行病学、发病机制、诊断和当前治疗方法的最新信息，并总结了fremanezumab作为偏头痛治疗药物的证据。
